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OBJECTIVES: Global quality of life (QoL) is an individ-
ual’s overall evaluation of their quality of life, and can be
distinguished from the total QoL, which is an aggregate
composed of items from various instruments. Hyland et
al. have developed a new global quality of life scale (Hy-
land scale). The purpose of this study was to investigate
how the Hyland scale evaluates the perception of health
status in patients with asthma, and to compare the Hy-
land scale with generic and asthma-specific instruments.
METHODS: A total of 167 patients with chronic asthma
(age: 48  8 yr, 83 males) completed pulmonary function
testing, a measurement of their airway hyperresponsive-
ness, their dyspnea rating (Medical Research Council
dyspnea scale), and assessments of their anxiety and de-
pression (HADS; Hospital Anxiety and Depression Scale)
and assessments of their health status. The global QoL
was assessed using the Hyland scale, and the health sta-
tus was assessed using the SF-36 and the Living With
Asthma Questionnaire (LWAQ).
RESULTS: The score on the Hyland scale was normally
distributed (mean:[SD]:74[14]). The test-retest reliability
of the Hyland scale was found to be high (intraclass coef-
ficient  0.80), and mild correlations were noted be-
tween the Hyland scale and the Anxiety and Depression
on the HADS (Spearman’s rank correlation coefficient
[Rs]  0.28 and 0.40 respectively). The Hyland scale
had a moderate correlation with the LWAQ (Rs  0.20),
and had its strongest correlation with the General Health
(Rs  0.48) among the 8 subscales on the SF-36. The Hy-
land scale did not have any significant correlations with
the FEV1, peak expiratory flow rates, or the degree of
airway hyperresponsiveness. Multiple regression analysis
showed that the Hyland scale was affected by the Anxi-
ety on the HADS, but its cumulative coefficient of deter-
mination was very low (R2  0.02).
CONCLUSIONS: The Hyland scale had mild correla-
tions with generic and disease-specific measures, and did
not correlate well with clinical parameters. The Hyland
scale may give insight into other aspects of the health sta-
tus different from what generic and disease-specific in-
struments evaluate.
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OBJECTIVE: To evaluate the potential cost savings of
asthma drug therapy in helping reduce incurred health-
care expenses.
METHODS: We integrated 18 months of drug and med-
ical claims for 49,059 continuously eligible, unique indi-
viduals. Individuals were eligible for study inclusion if, in
the first 12 months, they received a medical diagnosis of
asthma (ICD-9  493) or filled an asthma-related drug
prescription. A total of 1,830 asthmatics were included in
the study after exclusions for those under age 6, those over
age 64, and those with chronic obstructive pulmonary dis-
ease. We compared total health costs by type of medica-
tion (controller vs. any/none and any vs. none) in the last 6
months after stratifying for age and comorbidity. 
RESULTS: Annualized total health care costs were con-
sistently lower for those on controller medications than
those not on controller medications. The difference was
most noticeable for asthmatics on controller medications
who were 40–64 years old (n  261); these individuals
had an average annual expense of $5,961 versus $10,138
for those who were not on controller medications (n 
258) (p  .07). The relationship between the use of any
asthma medication and costs was inconsistent. While the
differences in cost for those under the age of 18 and over
the age of 39 were insignificant, there was a significant
difference among individuals between the ages of 18–39
who had lower comorbidity scores. Those individuals on
any asthma medication (n  176) had an average annual-
ized expense of $1,400 in the follow-up period, versus
$4,143 among those who were not on these medications
(n  52) (p  .0022).
CONCLUSION: Our study seems to confirm the findings
of others, suggesting that the use of controller medica-
tions, may reduce total health care costs. We plan now fur-
ther research to evaluate the effects of patient drug utiliza-
tion on these cost outcomes.
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OBJECTIVES: This study analyzed managed care claims
to find out how zafirlukast, a recently established oral
asthma therapy, is being prescribed in clinical practice
and to evaluate the effects of zafirlukast therapy on
healthcare resource utilisation.
METHODS: We examined the claims of 780 patients
(12 years) who participated in a Northeastern US man-
aged care plan and had received at least 3 months’ therapy
with zafirlukast, including at least one repeat prescription.
Baseline medications were determined 3 months before the
start of zafirlukast. Use of healthcare services, including
number of outpatient visits, inpatient stays, emergency de-
partment visits, and asthma-related drug prescriptions,
were compared between 3 months before and 3 months af-
ter commencing zafirlukast.
RESULTS: Zafirlukast was prescribed to patients on a
variety of baseline medications, with 72% already receiv-
